Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy

被引:14
|
作者
Bedke, Jens [1 ]
Chun, Felix K-H [3 ]
Merseburger, Axel [4 ]
Scharpf, Marcus [2 ]
Kasprzyk, Kathrin [1 ]
Schilling, David [1 ]
Sievert, Karl-Dietrich [1 ]
Stenzl, Arnulf [1 ]
Kruck, Stephan [1 ]
机构
[1] Univ Tubingen, Dept Urol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[4] Hannover Med Sch, Dept Urol & Urooncol, Hannover, Germany
关键词
renal cell cancer; systemic inflammation; biomarkers; CRP; WBC; threshold; predictive accuracy; CANCER-SPECIFIC SURVIVAL; VALIDATION; BIOMARKER; MORTALITY; IMPACT; MODEL;
D O I
10.1111/j.1464-410X.2012.11642.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To re-evaluate the prognostic and predictive significance of the preoperative white blood cell (WBC) count and C-reactive protein (CRP) that independently predicts patient prognosis and to determine optimal threshold values for CRP. PATIENTS AND METHODS From 1996 to 2005, 327 patients with surgery for clear cell renal cell carcinoma were retrospectively evaluated. Cox proportional hazard models were used, adjusted for the effects of tumour stage, size, Fuhrman grade and Karnofsky index, to evaluate the prognostic significance of WBC count and CRP and to identify threshold values. Identified thresholds were correlated with clinicopathological parameters and used to estimate cancer-specific survival. To prove any additional predictive accuracy of the identified threshold it was compared with a clinicopathological base model using the Harrell concordance index (c-index). RESULTS In univariable analyses WBC count was a significant prognostic marker at a concentration of 9.5/mu L (hazard ratio [HR] 1.83) and 11.0/mu L (HR 2.09) and supported CRP values of 0.25 mg/dL (HR 6.47, P < 0.001) and 0.5 mg/dL (HR 7.15, P < 0.001) as potential threshold values. If adjusted by the multivariable models WBC count showed no clear breakpoint, but a CRP value of 0.25 mg/dL (HR 2.80, P = 0.027) proved to be optimal. Reduced cancer-specific survival was proved for CRP 0.25 mg/dL (median 69.9 vs 92.3 months). Median follow-up was 57.5 months with 72 (22%) tumour-related deaths. The final model built by the addition of CRP 0.25 mg/dL did not improve predictive accuracy (c-index 0.877) compared with the clinicopathological base model (c-index 0.881) which included TNM stage, grading and Karnofsky index. CONCLUSIONS Multivariable analyses revealed that an optimal breakpoint of CRP at a value of 0.25 mg/dL was best to stratify patients at risk of cancer-specific mortality, but CRP 0.25 mg/dL added no additional information in the prediction model. Therefore we cannot recommend measuring CRP as the traditional parameters of TNM stage, grading and Karnofsky index are already of high predictive accuracy.
引用
收藏
页码:E771 / E777
页数:7
相关论文
共 50 条
  • [21] Preoperative C-reactive protein combined with SSIGN score as an independent predictor of cancer-specific survival in patients with clear cell renal cell carcinoma
    Herrel, Lindsey Allison
    Tai, Caroline Gar-Ling
    Westby, Ruth
    Ogan, Ken
    Canter, Daniel
    Pattaras, John
    Nieh, Peter
    Master, Viraj A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [22] Absolute Preoperative C-Reactive Protein Predicts Metastasis and Mortality in the First Year Following Potentially Curative Nephrectomy for Clear Cell Renal Cell Carcinoma
    Johnson, T. V.
    Abbasi, A.
    Owen-Smith, A.
    Young, Andrew
    Ogan, K.
    Pattaras, J.
    Nieh, P.
    Marshall, F. F.
    Master, V. A.
    JOURNAL OF UROLOGY, 2010, 183 (02): : 480 - 485
  • [23] Role of C-reactive protein as a biomarker for renal cell carcinoma
    Saito, Kazutaka
    Kihara, Kazunori
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (12) : 1979 - 1989
  • [24] A novel preoperative inflammatory marker prognostic score in patients with clear cell renal cell carcinoma.
    Sekar, Rishi Robert
    Patil, Dattatraya
    Pearl, Jeff
    Baum, Yoram
    Kucuk, Omer
    Harris, Wayne B.
    Carthon, Bradley Curtis
    Alemozaffar, Mehrdad
    Filson, Christopher Paul
    Ogan, Kenneth
    Master, Viraj A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [25] Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma
    Petitprez, Florent
    Ayadi, Mira
    de Reynies, Aurelien
    Fridman, Wolf H.
    Sautes-Fridman, Catherine
    Job, Sylvie
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Immunohistochemical Analysis of Prognostic Protein Markers for Primary Localized Clear Cell Renal Cell Carcinoma
    Weber, Thomas
    Meinhardt, Matthias
    Zastrow, Stefan
    Wienke, Andreas
    Fuessel, Susanne
    Wirth, Manfred P.
    CANCER INVESTIGATION, 2013, 31 (01) : 56 - 64
  • [27] Increased Expression of Intratumoral C-Reactive Protein Predicts Mortality in Patients with Localized Clear Cell Renal Cell Carcinoma
    Ali, S.
    Master, V. A.
    Abbasi, A.
    Kucuk, O.
    Young, A. N.
    Ogan, K.
    Pattaras, J. G.
    Nieh, P. T.
    Marshall, F. F.
    Osunkoya, A. O.
    LABORATORY INVESTIGATION, 2011, 91 : 176A - 176A
  • [28] Evaluation of serial measurements of C-reactive protein: Albumin ratio in patients with clear cell renal cell carcinoma.
    Patil, Dattatraya H.
    Anastasiades, Ella N.
    Torlak, Mersiha
    Lay, Aaron
    Alemozaffar, Mehrdad
    Pattaras, John
    Kucuk, Omer
    Carthon, Bradley Curtis
    Bilen, Mehmet Asim
    Ogan, Kenneth
    Master, Viraj A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
    Mizuno, R.
    Yasumizu, Y.
    Tanaka, N.
    Morita, S.
    Takeda, T.
    Matsumoto, K.
    Kosaka, T.
    Asanuma, H.
    Oya, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1566 - S1566
  • [30] PROGNOSTIC IMPACT OF C-REACTIVE PROTEIN KINETICS FOR ADVANCED RENAL CELL CARCINOMA TREATED WITH SUNITINIB
    Fujita, Tetsuo
    Iwamura, Masatsugu
    Hirayama, Takahiro
    Ishii, Daisuke
    Tabata, Ken-ichi
    Matsumoto, Kazumasa
    Yoshida, Kazunari
    JOURNAL OF UROLOGY, 2013, 189 (04): : E788 - E788